Marrita Rabadi

Ms. Marrita Rabadi

College of Medicine, Qatar University, Doha, Ad Dawḩah, Qatar
orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2026 in Leukemia & Lymphoma
Verified
Journal Article
Open access
SMShehab F. Mohamed
Shehab F. Mohamed
FAFadel Alqatati
Fadel Alqatati
Marrita RabadiMarrita Rabadi
Marrita Rabadi
MBMaria Benkhadra
Maria Benkhadra
ATAngham Ibrahim Tartour
Angham Ibrahim Tartour
NGNaseema Gangat
Naseema Gangat
Myelodysplastic syndromes (MDS) are rare in women of reproductive age, and evidence regarding pregnancy outcomes remains limited. A systematic literature search identified 21 publications reporting MDS recognized before or during pregnancy, encompassing 69 pregnancies. The data were descriptively analyzed and stratified by timing of MDS diagnosis. Of the 69 pregnancies, 52% involved women diagnosed with MDS before conception, while 48% were diagnosed during pregnancy. Leukemic transformation occurred exclusively among cases diagnosed during pregnancy. The majority of pregnancies resulted in live births, with rates exceeding 93% in both groups, and neonatal complications being uncommon. MDS diagnosed during pregnancy appears to confer higher maternal risk, underscoring the need for early recognition and multidisciplinary management. This scoping review suggests that pregnancy can be successfully carried to term in selected women with MDS, particularly when disease stability is established prior to conception.

1 January 2026 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
SMShehab F. Mohamed
Shehab F. Mohamed
RARafal AlShebly
Rafal AlShebly
HSHawraa Shawaylia
Hawraa Shawaylia
AEAnil Elahie
Anil Elahie
RGRola Ghasoub
Rola Ghasoub
HCHonar Cherif
Honar Cherif
Background: Thrombosis remains a clinically important complication of acute promyelocytic leukemia (APL), coexisting with the prototypical hemorrhagic diathesis. Data from Gulf Cooperation Council (GCC) populations are limited in addition to data specifically about thrombosis, which is heterogenous in general. Objectives: To describe the incidence, clinical characteristics, treatment, and outcomes of thrombotic events in patients with APL treated at a tertiary center in the GCC. Methods: We conducted a retrospective cohort study of 75 consecutive patients with newly diagnosed APL managed at a single tertiary center. Baseline demographic variables (age, sex, regional background), hematologic parameters (hemoglobin, leukocyte, platelet counts), and coagulation indices (fibrinogen, activated partial thromboplastin time, prothrombin time, international normalized ratio, and D-dimer) were compared between patients with and without thrombosis. Thrombotic event type, timing, antithrombotic management, bleeding complications, and mortality (including early mortality within 30 days) were recorded. Results: Eleven of 75 patients (14.7%) developed thrombosis. Baseline demographic characteristics, hemoglobin level, leukocyte count, platelet count, fibrinogen, and activated partial thromboplastin time were comparable between patients with and without thrombosis, whereas prothrombin time, international normalized ratio, and D-dimer levels were numerically higher in patients who developed thrombosis. Most thrombotic events (73%) occurred during active therapy, and the majority were venous (55%). Pulmonary embolism accounted for 36% of all thrombotic episodes, and catheter-associated thromboses represented a clinically relevant subset. Anticoagulation was initiated in 45% of patients with thrombosis and antiplatelet therapy in 18%. Bleeding episodes occurred in 36% of patients who experienced thrombosis. Thrombosis was associated with a 27% all-cause mortality. Conclusions: In this GCC APL cohort, thrombosis, though less frequent than bleeding, emerged as a serious and clinically significant manifestation associated with substantial morbidity and mortality. These findings underscore the need for vigilant thrombo-hemorrhagic assessment and individualized antithrombotic strategies, particularly during induction and early consolidation therapy.

HSHiba Farooq Siddiqui
Hiba Farooq Siddiqui
SSSundus Farooq Siddiqui
Sundus Farooq Siddiqui
Marrita RabadiMarrita Rabadi
Marrita Rabadi
ASAnfal Mohamed Shalaby
Anfal Mohamed Shalaby
AAAbdullatif Ibrahim Al-Hor
Abdullatif Ibrahim Al-Hor
ATAngham Ibrahim Tartour
Angham Ibrahim Tartour
Glyphosate herbicide has been linked with airway diseases in adults. Evidence remains inconsistent, without investigations conducted in youthful populations. This study aims to examine the association between glyphosate and obstructive airway diseases in adult and youth samples in the National Health and Nutrition Examination Survey. Glyphosate exposure was categorized into tertiles. Separate multiple logistic regressions were conducted for adults and youths, adjusting for relevant covariates. Analyses were stratified by age. Sensitivity analyses explored associations with past-year asthma-related events. In total, 4031 adults and 1692 youths were included. There was a significant dose–response relationship between glyphosate and airway diseases in adults (tertile 2: aOR = 1.17, 95% UI: 0.94, 1.46, p = 0.15; tertile 3: aOR = 1.29, 95% UI: 1.02, 1.62, p = 0.03). Weak associations were shown between glyphosate and asthma in the youth sample (aOR = 1.08, 95% UI: 0.74, 1.58, p = 0.69); however, the relationship was more pronounced in adolescents (aOR = 1.33, 95% UI: 0.82, 2.15, p = 0.24). A dose–response pattern was observed between recent exposure and temporal outcomes in adults, reaching up to 75% higher odds of past-year asthma attacks among participants with glyphosate levels at the third tertile (tertile 3: aOR = 1.75, 95% UI: 0.92, 3.36, p = 0.09). These warrant timely monitoring and prevention strategies, with future research focusing on investigating longitudinal associations.

1 August 2026 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
Marrita RabadiMarrita Rabadi
Marrita Rabadi
ZHZaeem Hussain
Zaeem Hussain
SSSundus Farooq Siddiqui
Sundus Farooq Siddiqui
HSHiba Farooq Siddiqui
Hiba Farooq Siddiqui
MNMichail Nomikos
Michail Nomikos
MAMohammed Seed Ahmed
Mohammed Seed Ahmed
Background: Vitamin D is an important immunomodulator in host defense against Mycobacterium tuberculosis, yet most tuberculosis-related research has focused on the vitamin D receptor (VDR). The contribution of vitamin D metabolism genes, particularly cytochrome P450 (CYP) enzymes, remains less clearly defined. Methods: We conducted a narrative review examining the role of major vitamin D–metabolizing enzymes, including CYP2R1, CYP27A1, CYP27B1, and CYP24A1, in tuberculosis susceptibility, immune regulation, and treatment response, with additional focus on diabetes mellitus as a major comorbidity. Evidence from genetic association studies, observational studies, mechanistic experiments, and clinical data was synthesized. Results: Vitamin D metabolism enzymes influence intracellular vitamin D activation and inactivation, affecting antimicrobial peptide production, autophagy, cytokine signaling, and macrophage-mediated clearance of M. tuberculosis. Genetic and epigenetic variation in these pathways may contribute to differences in tuberculosis risk and prognosis. Diabetes mellitus may further disrupt these mechanisms through chronic hyperglycemia, oxidative stress, inflammation, impaired macrophage and T-cell function, and alterations in vitamin D metabolism, potentially increasing tuberculosis susceptibility and worsening outcomes. However, direct evidence for several enzymes remains limited. Inconsistent findings from vitamin D supplementation trials suggest that circulating 25(OH)D may not accurately reflect functional vitamin D activity at infection sites. Current evidence is largely mechanistic, observational, and genetic, with few interventional studies. Conclusion: Vitamin D metabolism genes represent an underexplored but potentially important component of tuberculosis pathophysiology, particularly in patients with diabetes. Future work should prioritize genetically stratified host-directed approaches to identify patients most likely to benefit from vitamin D–based interventions.

1 January 2026 in Anemia
Verified
Journal Article
Open access
PDF file
SMShehab F. Mohamed
Shehab F. Mohamed
MAMohammed Abdulgayoom
Mohammed Abdulgayoom
AAAbdulrahman Al-Mashdali
Abdulrahman Al-Mashdali
Marrita RabadiMarrita Rabadi
Marrita Rabadi
EAElabbass Ali Abdelmahmuod
Elabbass Ali Abdelmahmuod
MYMohamed Yassin
Mohamed Yassin
Anemia represents one of the most clinically significant and therapeutically challenging complications in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), particularly in myelofibrosis. It is associated with increased symptom burden, transfusion dependence, and reduced overall survival. Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have consistently demonstrated increases in hemoglobin levels across multiple large randomized clinical trials in cardiovascular, renal, and metabolic diseases, raising interest in their potential role as modulators of erythropoiesis. This narrative review aimed to provide a comprehensive and mechanistically grounded overview of the role of SGLT2 inhibitors in improving hemoglobin levels in patients with MDS and MPN. A literature review was conducted using PubMed, Embase, and Google Scholar, focusing on the database from inception to June 2026. Studies evaluating SGLT2 inhibitors and hematologic outcomes in MDS, MDS/MPN overlap syndromes, myelofibrosis, or other MPNs were included. Both clinical and mechanistic studies were included. Current evidence in MDS and MPN remains limited to small observational cohorts, retrospective studies, and case reports. Across the available clinical studies in patients with MDS and MPN, SGLT2 inhibitors were associated with increases in hemoglobin, generally ranging from 1.0 to 1.6 g/dL. Specifically, a median peak hemoglobin increase of approximately 1.2 g/dL was reported among non‐transfusion‐dependent patients with MDS/MDS‐MPN overlap receiving SGLT2 inhibitors, while patients with myelofibrosis receiving predominantly empagliflozin or dapagliflozin had a median increase of 1.0 g/dL. In MDS and myelofibrosis, these findings may reflect improvement in ineffective erythropoiesis, whereas in non‐anemic MPN subtypes, the observed changes may instead represent erythrocytosis. Preliminary observational findings suggest a potential erythropoietic effect of SGLT2 inhibitors; however, whether this translates into a therapeutic benefit in MDS or MPN remains uncertain and requires prospective and mechanistic validation.

13 August 2026 in European Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
EAElrazi Ali
Elrazi Ali
Marrita RabadiMarrita Rabadi
Marrita Rabadi
RARuba Adel Aweer
Ruba Adel Aweer
ESEihab Subahi
Eihab Subahi
EAElabbass Ali Abdelmahmuod
Elabbass Ali Abdelmahmuod
SMShehab Mohamed
Shehab Mohamed
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used in the management of type 2 diabetes mellitus (T2DM) due to their survival benefits. However, these agents are associated with increases in hemoglobin (Hgb) and hematocrit (Hct), raising concern for secondary polycythemia or erythrocytosis and potential thrombotic risk. The clinical significance of these hematologic changes remains unclear. Methods: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines. PubMed, Scopus, and Embase were searched up to February 2026 for studies evaluating the effect of SGLT2 inhibitors on hematologic parameters in adults with T2DM. Patients with primary polycythemia, end-stage renal disease (ESRD), or heart failure were excluded. Primary outcomes were changes in Hgb and Hct. Secondary outcomes included the incidence of erythrocytosis/polycythemia and thrombotic events. Results: A total of 10 studies met inclusion criteria, comprising randomized and observational studies, with follow-up ranging from 8 weeks to 24 months. SGLT2 inhibitors, including empagliflozin, dapagliflozin, and canagliflozin, were consistently associated with increases in Hgb and Hct. Across three randomized controlled trials, SGLT2 inhibitors significantly increased hematocrit (3 studies, 171 patients, pooled mean difference + 2.29%, 95% CI 1.48 to 3.09) and hemoglobin (3 studies, 171 patients, pooled mean difference + 0.51 g/dL, 95% CI 0.28 to 0.74) compared with placebo. Real-world data (9,646 patients) reported an increase in polycythemia prevalence from 2.4% to 9.7%, with severe cases in 1.4% of patients. Limited data suggested a potential association with thrombotic events, with one observational study of 100 patients with JAK2-unmutated erythrocytosis reporting a 10% event rate. Hematologic changes were observed early after treatment initiation and appeared reversible following drug discontinuation. Conclusions: In patients with type 2 diabetes, ESRD, or heart failure, SGLT2 inhibitor use is associated with consistent increases in hemoglobin and hematocrit. Although these effects may contribute to cardiovascular benefit, a subset of patients may develop clinically significant erythrocytosis. Clinicians should be aware of this potential effect and monitor high-risk individuals. Larger prospective studies are needed to better define the clinical significance of these findings.